The 2018 Australian Heart Failure (HF) guidelines (October 2018) gave a strong recommendation
for commencing sodium-glucose co-transporter-2 inhibitors (SGLT-2i) in HF patients
with type 2 diabetes mellitus (T2DM). This was based on strong evidence demonstrating
that SGLT-2i reduce major adverse cardiac events and HF hospitalisation in this patient
population. Currently, the uptake of prescribing SGLT-2i for HF with T2DM is unclear.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Heart, Lung and CirculationAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
112
Identification
Copyright
© 2021 Published by Elsevier Inc.
